1. Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation 
Mihoko Kawabata, MD, PhD, Masahiko Goya, MD, PhD, Yoshihide Takahashi, MD, PhD, Shingo Maeda, MD, PhD, Atsuhiko Yagishita, MD, PhD, Masahiro Sekigawa, MD, Kiko Akiyoshi, MD, Tasuku Yamamoto, MD, Takatoshi Koyama, MD, PhD, Kenzo Hirao, MD, PhD 
Canadian Journal of Cardiology 
Volume 35, Issue 6, Pages (June 2019)
DOI: /j.cjca
Copyright © 2019 Canadian Cardiovascular Society Terms and Conditions

2. Figure 1
Flow chart for subject selection. APTT, activated partial thromboplastin time; DOAC, direct oral anticoagulants; NVAF, nonvalvular atrial fibrillation; PT, prothrombin time.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2019 Canadian Cardiovascular Society Terms and Conditions

3. Figure 2
The distribution of activated partial thromboplastin time (APTT) values for direct thrombin inhibitors and prothrombin time (PT) values for FXa inhibitors. In patients with 2 or more measurements, the measurements were averaged. The red bars indicate the distribution of the excessive prolongation group defined as those in whom PT or APTT was prolonged by more than 2 standard deviations over the median value for each direct oral anticoagulant. The blue bars indicate the distribution of the group without excessive prolongation. In 88 patients (5.7%), coagulation time was excessively prolonged.
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2019 Canadian Cardiovascular Society Terms and Conditions

4. Figure 3
Kaplan-Meier curves for the thromboembolic (A) and bleeding events (B) in the group with excessive prolongation (EP group) and in the group without excessive prolongation (non-EP group).
Canadian Journal of Cardiology  , DOI: ( /j.cjca )
Copyright © 2019 Canadian Cardiovascular Society Terms and Conditions